Investigation of Cannabinoid Receptor Agonist Dronabinol in Patients With Functional Chest Pain
Status:
Withdrawn
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
In a recent study, Dronabinol was shown to reduce symptoms in patients with Functional Chest
Pain (non-cardiac chest pain). Additionally, metabolic measures and patients' weights were
not adversely affected by this regiment. In fact, some cholesterol measures trended in a
favorable direction with Dronabinol. The study lasted 28 days and patients took Dronabinol
twice daily. The goal of this current study focuses on reducing the dose of Dronabinol to see
if the same goals can be achieved. More so, the study will be extended to 12 weeks to gain a
more longitudinal picture of therapy with Dronabinol. It is hypothesized that reducing the
dose and extending the duration will continue to show an improvement in symptoms as well as
no adverse metabolic outcomes.